A Study of Sigvotatug Vedotin in Advanced Solid Tumors (NCT04389632)
A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors. The study will have four parts. * Part A of the study will find out how much sigvotatug vedotin should be given to participants. * Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors. * Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs. * Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors. * In Parts C and D, participants will receive sigvotatug vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin.
Who can join: Review the eligibility criteria below.
Location: Alaska Oncology and Hematology — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (158 Sites)
Showing the first 25 of 158 sites.
- Alaska Oncology and Hematology — Anchorage, Alaska
- Highlands Oncology Group — Fayetteville, Arkansas
- Highlands Oncology Group — Rogers, Arkansas
- Highlands Oncology Group — Springdale, Arkansas
- Providence Medical Foundation — Anaheim, California
- Providence Medical Foundation — Fullerton, California
- Providence St. Jude Medical Center Virginia K Crosson and Infusion Center — Fullerton, California
- Cancer and Blood Research Center, LLC — Los Alamitos, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
- The Regents of the University of California — Los Angeles, California
- UCLA Department of Medicine-Hematology/Oncology — Los Angeles, California
- UCLA Department of Medicine - Hematology & Oncology — Santa Monica, California
- Cancer AND Blood Specialty Clinic — Torrance, California
- American Oncology Partners, PA. a Florida professional service corporation, d/b/a Vista Oncology — Fort Myers, Florida
- Florida Cancer Specialists & Research Institute, LLC — Fort Myers, Florida
- Memorial Cancer Institute — Hollywood, Florida
- Memorial Healthcare System — Hollywood, Florida
- Florida Cancer Specialists — Orlando, Florida
- Memorial Cancer Institute at Memorial Hospital West — Pembroke Pines, Florida
- Memorial Hospital West — Pembroke Pines, Florida
- Ingalls Family Care Center — Calumet City, Illinois
- UChicago Medicine - River East — Chicago, Illinois
- The University Of Chicago — Chicago, Illinois
- University of Chicago Medical Center — Chicago, Illinois
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small Cell Lung
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib — Los Angeles, California
- Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer — Washington D.C., District of Columbia
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer — La Mesa, California
Explore by condition: All Carcinoma, Non-Small Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.